- Xebra Brands (XBRA) has commenced formal cannabis cultivation in the Netherlands, including THC varietals
- Xebra was one of only five companies selected by the Dutch government to participate in trial medicinal cannabis cultivation
- The company is working towards a 6-year contract to co-supply all pharma-grade cannabis to be sold in the Netherlands
- Xebra’s operations in the Netherlands is led by Harry von Duijne, an experienced cannabis horticulture expert with more than two decades of practicing horticulture
- Xebra Brands is an international cannabis cultivation and product company
- Xebra Brands Ltd. (XBRA) is up 1.72 per cent on the day, trading at C$0.295 per share at 11:45 am EST
Xebra Brands (XBRA) has commenced formal cannabis cultivation in the Netherlands, including THC varietals.
As one of only five companies selected by the Dutch government to participate in trial medicinal cannabis cultivation, Xebra is hoping to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to US$79 million, to co-supply all pharma-grade cannabis to be sold in the Netherlands.
Cultivation in the Netherlands is conducted in Xebra’s indoor facility. Xebra’s specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine-tasting terpene profiles, with a growth cycle of 12-16 weeks.
Xebra’s Director of Operations in the Netherlands, Harry von Duijne, is an experienced cannabis horticulture expert with more than two decades of practicing horticulture. He had a leading role at Bedrocan NL® from 2014 and 2017, where he was responsible for managing every aspect of operations of a state-of-the-art cannabis facility, from construction through cultivation and processing, quality management, and GMP certification.
Xebra Brands is an international cannabis cultivation and product company.
Xebra Brands Ltd. (XBRA) is up 1.72 per cent on the day, trading at C$0.295 per share at 11:45 am EST.